25-Nov-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p
6-Nov-2025 3:00 PM CST - Business Wire Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2025. During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rockets AAV cardiovascular gene therapy portfolio, said Gaurav Sha
28-Aug-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 2025 Cantor Fitzgerald Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and manag
7-Aug-2025 3:00 PM CST - Business Wire Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took m
27-May-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome.
8-May-2025 3:01 PM CST - Business Wire Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ending March 31, 2025. "Rocket maintained strong momentum during the first quarter, and we look forward to sharing updates of our recent progress starting with initial data from the Phase 1 study
3-Apr-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that management will participate in the 24th Annual Needham Virtual Healthcare Conference taking place on April 8, 2025. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat at 8:45 a.m. ET on Tuesday, April 8. A webcast of the fire
25-Nov-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference in Miami. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat on Tuesday, December 2, at 7:55 a.m. ET and host investor meetings. A webcast of the p
6-Nov-2025 3:00 PM CST - Business Wire Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the third quarter ending September 30, 2025. During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rockets AAV cardiovascular gene therapy portfolio, said Gaurav Sha
28-Aug-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the 2025 Cantor Fitzgerald Global Healthcare Conference and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat and manag
7-Aug-2025 3:00 PM CST - Business Wire Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the second quarter ending June 30, 2025. The second quarter of 2025 marked an important inflection point for Rocket as we refined our strategic focus around our AAV cardiovascular gene therapy platform and took m
27-May-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing an integrated pipeline of genetic therapies for rare diseases, today announced an update related to RP-A501, its investigational gene therapy for Danon disease. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The SAE involved clinical complications related to a capillary leak syndrome.
8-May-2025 3:01 PM CST - Business Wire Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ending March 31, 2025. "Rocket maintained strong momentum during the first quarter, and we look forward to sharing updates of our recent progress starting with initial data from the Phase 1 study
3-Apr-2025 6:00 AM CST - Business Wire Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that management will participate in the 24th Annual Needham Virtual Healthcare Conference taking place on April 8, 2025. Gaurav Shah, M.D., Chief Executive Officer, will take part in a fireside chat at 8:45 a.m. ET on Tuesday, April 8. A webcast of the fire
